# RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

> **NCT00358215** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 2278 (actual)

## Conditions studied

- Heart Failure
- Anemia
- Cardiovascular Disease
- Ventricular Dysfunction
- Congestive Heart Failure

## Interventions

- **DRUG:** Darbepoetin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00358215
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-01
- **Primary completion:** 2012-10-11
- **Final completion:** 2012-10-11
- **Target enrollment:** 2278 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358215, "RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00358215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*